Dianthus Therapeutics announced positive Phase 2 data for its selective complement inhibitor, claseprubart, targeting generalized myasthenia gravis (gMG). The antibody met multiple efficacy endpoints in this neuromuscular disorder characterized by muscle weakness. Based on these results, the company plans to progress to pivotal Phase 3 trials, aiming to address the competitive gMG treatment landscape with a potentially differentiated therapeutic. This advancement adds momentum to neuromuscular disease drug development efforts.